Navigation Links
Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
Date:11/19/2008

ctober 24, 2008, income from operations of $7.3 million compared to a loss from operations of $11.5 million in the same period of fiscal 2008.

Debt repurchase / other income

During the recently completed quarter, the company repurchased $40.4 million of its outstanding convertible debt for a total consideration of $34.9 million, and recorded a net gain of $4.6 million, including the impact of the accelerated amortization of deferred issuance costs.

Net income

The company reported net income of $8.3 million, or $0.14 per diluted share, for the second quarter, compared with a net loss of $4.1 million, or $0.15 per share, in the second quarter of fiscal 2008. Although the gain on early extinguishment of the convertible debt is included in the calculation of net income, as per the applicable accounting rules it is excluded from the calculation of net income per diluted share.

Balance sheet and cash flow

The company generated positive operating cash flow of $4.0 million during the quarter. The overall decrease of $31.8 million in cash to $69.3 million in the recently completed quarter resulted primarily from the repurchase of convertible debt referenced above.

Results and objectives

"Fiscal 2009 performance continues to be strong," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "Our financial results have improved in each of the last six quarters. The company again recorded operating income, positive cash flow from operations and net income. Our core U.S. epilepsy business showed excellent growth, with revenues increasing by an estimated 32% over the prior year.

"Over the last 12 months, we estimate that approximately 3,600 new patients have chosen VNS Therapy(TM) in the U.S. market, and approximately 5,700 worldwide. In addition, over 2,600 patients worldwide have replaced their VNS generator up
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
2. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
3. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
4. Cyberonics to Present at UBS Global Life Sciences Conference
5. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
6. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results
7. Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference
8. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
11. Cyberonics Licenses Obesity-Related Patents
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Vivakor Announces New Acquisition Strategy 2Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility 2Grapes and Grape Products Show Exciting Potential in Optimizing Health 56833 1Grapes and Grape Products Show Exciting Potential in Optimizing Health 56833 2Grapes and Grape Products Show Exciting Potential in Optimizing Health 56833 3Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 1Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 2Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 3Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 4Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 5Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 6Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 7Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research 28ASBMR 29 Meeting 4964 8Polaroid 28R 29 Continuing Tradition of Support for Boston Marathon 28R 29 Jimmy Fund 28R 29 Walk 56830 1Polaroid 28R 29 Continuing Tradition of Support for Boston Marathon 28R 29 Jimmy Fund 28R 29 Walk 56830 2